⚠️ Metabolic syndrome describes a cluster of cardiometabolic risk factors including central obesity, insulin resistance / impaired glucose regulation, hypertension, and atherogenic dyslipidaemia. It is associated with an increased risk of type 2 diabetes, cardiovascular disease, and stroke.
📖 About
- Also called insulin resistance syndrome or Syndrome X.
- The key clinical pattern is central adiposity + glucose dysregulation + raised blood pressure + abnormal lipids.
- In UK practice, there is no single NICE treatment pathway for metabolic syndrome itself; management focuses on identifying and treating each risk factor and estimating overall cardiovascular risk.
- Metabolic syndrome / pre-diabetes is recognised as a factor that increases future cardiovascular risk.
⚠️ Aetiology & Pathophysiology
- The main driver is insulin resistance, usually linked to visceral / central adiposity.
- Adipose tissue dysfunction contributes to atherogenic dyslipidaemia, endothelial dysfunction, low-grade inflammation, and a pro-thrombotic state.
- Mechanistically, altered adipokines and inflammatory mediators help explain why abdominal obesity is closely linked to diabetes, hypertension, and vascular disease.
- Associated conditions can include non-alcoholic fatty liver disease, PCOS, and sometimes hyperuricaemia/gout, but these are associated features rather than core diagnostic criteria.
📏 Diagnostic Criteria (IDF 2005)
One commonly used definition is the IDF 2005 definition: central obesity (using ethnicity-specific waist circumference thresholds) plus any 2 of the following.
- Raised triglycerides: ≥1.7 mmol/L or specific treatment for this abnormality.
- Reduced HDL cholesterol: <1.03 mmol/L in men or <1.29 mmol/L in women, or specific treatment for this abnormality.
- Raised blood pressure: systolic ≥130 mmHg or diastolic ≥85 mmHg, or treatment for previously diagnosed hypertension.
- Raised fasting plasma glucose: ≥5.6 mmol/L or previously diagnosed type 2 diabetes.
🧾 Risk Factors
- Central obesity and weight gain.
- Physical inactivity and calorie-dense diet.
- Increasing age.
- Family history of type 2 diabetes or cardiovascular disease.
- Higher risk in some ethnic groups, including South Asian populations, who may develop cardiometabolic risk at lower BMI and waist thresholds.
- Associated conditions such as PCOS, hypertension, and previous gestational diabetes also increase diabetes risk.
🩺 Clinical Features
- Often asymptomatic and found on routine review or health checks.
- Typical findings are central adiposity, raised BP, impaired fasting glucose / diabetes, and high triglycerides with low HDL.
- Some people present with symptoms of diabetes such as polyuria, polydipsia, or fatigue.
- Look for associated disease such as fatty liver disease, sleep apnoea, or PCOS.
🔍 Related / Differential Diagnoses
- Type 2 diabetes mellitus.
- Primary hypertension.
- Dyslipidaemia.
- NAFLD / MASLD.
- PCOS.
- Cushing’s syndrome or other secondary causes of obesity, diabetes, or hypertension where clinically suspected.
🧪 Assessment in UK practice
- Measure BMI and waist circumference.
- Check blood pressure.
- Assess glycaemia with HbA1c and/or fasting glucose depending on context.
- Check a lipid profile.
- Estimate overall cardiovascular risk with QRISK3 for primary prevention where appropriate.
- Assess for coexisting conditions such as chronic kidney disease, type 2 diabetes, and fatty liver disease.
💊 Management
- Lifestyle intervention is the cornerstone:
- Weight reduction, especially reduction in central adiposity.
- Regular physical activity, including both aerobic and resistance exercise.
- Healthier diet with lower ultra-processed food intake, improved fibre quality, and reduced excess calories.
- Smoking cessation and moderation of alcohol intake.
- Treat each risk factor according to NICE guidance:
- Lipids: assess CVD risk and offer statin therapy for primary prevention when indicated, typically using QRISK3.
- Blood pressure: manage according to NICE hypertension guidance.
- Glucose dysregulation / type 2 diabetes: manage according to NICE diabetes prevention and type 2 diabetes guidance.
- Overweight / obesity: use structured weight-management support where appropriate.
- Multifactorial risk reduction is key because treating BP, glucose, lipids, and weight together reduces cardiovascular risk more than addressing one factor alone.
- Monitoring should include repeat review of weight, waist, BP, HbA1c/glucose status, lipids, renal function, and overall cardiovascular risk.
⚠️ Practical NICE points
- NICE recommends using a validated diabetes risk-assessment approach to identify adults at high risk of type 2 diabetes.
- For cardiovascular primary prevention, NICE recommends QRISK3 in adults aged 25–84 years where formal risk assessment is appropriate.
- Current NICE obesity guidance also explicitly covers central adiposity, which is highly relevant in metabolic syndrome.
📚 References
Clinical Examples
- ⚖️ Case 1 – Age 49: Central obesity, BP 148/92 mmHg, triglycerides 2.5 mmol/L, HDL 0.9 mmol/L, fasting glucose 6.4 mmol/L.
Interpretation: Meets IDF criteria for metabolic syndrome.
Management: weight-focused lifestyle intervention, formal CVD risk assessment with QRISK3, and treatment of hypertension/lipids according to NICE thresholds.
Teaching point: In UK practice, the label is less important than systematic treatment of each risk component.
- 🍔 Case 2 – Age 57: Woman with PCOS, central obesity, fasting glucose in the diabetic range, and raised triglycerides.
Interpretation: Significant insulin resistance with probable metabolic syndrome.
Management: confirm glycaemic status, manage as type 2 diabetes if diagnostic criteria are met, and address BP/lipid/weight risk in parallel.
Teaching point: PCOS is a strong clue to underlying insulin resistance and future cardiometabolic risk.
- 🩺 Case 3 – Age 62: Obesity, hypertension, low HDL, hypertriglyceridaemia, and fatty liver on imaging.
Interpretation: Cardiometabolic risk cluster consistent with metabolic syndrome.
Management: lifestyle treatment, BP control, lipid lowering if indicated, diabetes surveillance, and assessment of liver/metabolic complications.
Teaching point: Fatty liver is often the hepatic manifestation of insulin resistance and central adiposity.
